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1. INTRODUCTION {#ccd29134-sec-0005}
===============

Poland has had a highly efficient and widely accessible system of percutaneous treatment of coronary artery disease (CAD) with evenly distributed interventional cardiology facilities around the country and a high number of annual percutaneous coronary intervention (PCI) and primary percutaneous coronary intervention (pPCI) procedures per million inhabitants.[^1^](#ccd29134-bib-0001){ref-type="ref"}, [^2^](#ccd29134-bib-0002){ref-type="ref"}, [^3^](#ccd29134-bib-0003){ref-type="ref"} The distribution of cardiac catheterization centers has for many years met the requirements of ESC (European Society of Cardiology) guidelines with one cath lab for \<300,000 of inhabitants.[^4^](#ccd29134-bib-0004){ref-type="ref"} The development of the hospital network system for the interventional treatment of myocardial infarction has taken over two decades to complete.[^5^](#ccd29134-bib-0005){ref-type="ref"} However, with national lockdown being implemented on March 13, 2020 following the SARS‐CoV‐2 pandemic and shifting resources to the treatment of only acute cases, the principal assumptions of the existing hospital network for the percutaneous treatment of CAD in Poland has been jeopardized. Moreover, by administrative decisions, entire hospitals regardless of their primary specialization are being now transformed into dedicated centers for infectious diseases, in order to accommodate COVID‐19 patients. This also applies to the cardiology departments.

Our aim was to investigate based on the nationwide registry the impact of national lockdown and SARS‐CoV‐2 pandemic on the percutaneous treatment of CAD in Poland, as well as to provide a characteristic of COVID‐19 positive or suspected patients treated in interventional cardiology centers and their immediate procedural outcomes.

2. METHODS {#ccd29134-sec-0006}
==========

The ORPKI Registry (Polish National PCI Registry) in Poland gathers data on all percutaneous diagnostic and therapeutic procedures since 2004. A detailed description of the registry and annual reports has been published previously.[^1^](#ccd29134-bib-0001){ref-type="ref"}, [^6^](#ccd29134-bib-0006){ref-type="ref"} There are currently 163 catheterization laboratories in Poland reporting data for the ORPKI registry online everyday with 544 board‐certified PCI operators.

For this analysis, data on all percutaneous procedures (angiography or PCI) were extracted for the two‐month period (March 13--May 13, 2020). Data were gathered from the date of nationwide lockdown was administered (closed schools, nurseries, and universities, only essential workers allowed to commute to work, travel restrictions with the closing of national country borders) due to SARS‐CoV2 pandemic. The recommendations for the unified proceedings with COVID‐19 positive or suspected cases requiring percutaneous diagnostic and treatment have been issued by the Polish Association of Cardiovascular Interventions on March 19, 2020.[^7^](#ccd29134-bib-0007){ref-type="ref"} The ACC‐SCAI recommendations were also endorsed.[^8^](#ccd29134-bib-0008){ref-type="ref"} Patients with COVID‐19 suspicion (according to tho the triage recommendations of the National Institute of the Public Health and Ministry of Health) were treated as potential COVID‐19 positive. The working or established diagnosis of COVID‐19 was always available prior to any interventional procedure (angiography, PCI) and recorded in the web‐based ORPKI database. Swabs for molecular RT‐PCR testing were obtained always before any procedure. Analysis of COVID‐19 positive or suspected patients versus non‐COVID patients was performed. Additionally, a comparison of contemporary two‐month data versus analogous period for 2019 procedures (March 13--May 13, 2019) was carried out. Only peri‐procedural outcomes and complications were recorded in the database.

All patients provided informed consent. The study complied with the ethical principles for clinical research based on the Declaration of Helsinki with later amendments. No external funding was used to support this analysis.

3. STATISTICAL ANALYSIS {#ccd29134-sec-0007}
=======================

Continuous variables are presented as mean with *SD* or median with the first and the third quartile where applicable. Categorical variables are presented as numbers and percentages. Normality was assessed by Shapiro--Wilk test. Equality of variances was assessed using the Levene\'s test. Differences between two groups were compared using the Student\'s or the Welch\'s *t* test depending on the equality of variances for normally distributed variables. The Mann--Whitney *U* test was used for non‐normally distributed continuous variables. Categorical variables were compared by the Pearson\'s chi‐squared test or Fisher\'s exact test if at least 20% of cells in the contingency table had an expected count of less than 5 (Monte Carlo simulation for the Fisher test was used tables of dimensions higher than 2×2).

All of the baseline/demographic characteristics were included in the logistic regression model used in propensity score (PS) matching: age, weight, gender, history of stroke, history of MI, history of PCI, history of CABG, smoking status, presence of diabetes, presence of psoriasis, presence of hypertension, presence of any kidney disease, presence of COPD (chronic obstructive pulmonary disease) and indication for the procedure. Each COVID‐19 positive/suspected case was matched with 10 COVID‐19 negative cases, which showed the best balance between analyzed groups. PS matching was performed using the nearest neighbor algorithm. The groups were considered balanced if standardized differences for each of the analyzed baseline/demographic characteristics were lower than 10%.

Comparison of the total amount of contrast used during the procedure, total radiation dose during procedure, and odds for death between groups after PS matching was performed using a generalized linear mixed‐effects model to account for matching.

A similar sub‐analysis was performed only among patients with STEMI (ST‐Elevation Myocardial Infarction) indication with additional time from pain to first medical contact (FMC), time from pain to the balloon inflation or angiogram (in case of no pPCI was performed), and time from the FMC to the balloon inflation or angiogram after PS matching.

All confidence intervals are 95%, and all *p*‐values shown are two‐sided.

Statistical analysis was performed using the JMP version 14.3.0 (SAS Institute Inc., Cary, NC, 2019) and R, version 3.5.3 (R Foundation for Statistical Computing, Vienna, Austria, 2019) with the following packages: "MatchIt", version 3.0.2, "lme4", version 1.1--21 and "stddiff", version 3.0.

Analysis was based on all cases introduced into the database within specific timeframe. Due to small number of missing data PS, matching was performed on completed cases only.

4. RESULTS {#ccd29134-sec-0008}
==========

Of 163 cardiac catheterization centers in Poland, 12 (7.4%) were indefinitely closed down due to SARS‐CoV‐2 pandemic, and an additional 3 (1.8%) temporarily suspended (from 1 to 20 days) their operation. There were nine physicians (9 of 544; 1.7%) during a 2‐month period who had confirmed SARS‐CoV‐2 infection after performing coronary procedures in COVID‐19 positive/suspected patients.

There were 13,750 interventional cardiology procedures performed in Poland between March 13 and May 13, 2020, reported into the national ORPKI Registry. In 9093 (66%) cases, an acute coronary syndrome (ACS) was the primary diagnosis, and in the remaining 4,657 (34%) cases, it was an elective procedure for the chronic coronary syndrome. A comparison to the analogous period for the year 2019 is shown in Figure [1](#ccd29134-fig-0001){ref-type="fig"}. Mean times (in minutes) from pain to FMC, from pain to inflation/angiography and from FMC to inflation/angiography were: 217 (95% CI 207--227) versus 228 (95% CI 215--242) with *p* = .364; 312 (95% CI 302--323) versus 313 (95% CI 299--326) with *p* = .4639 and 127 (95% CI 121--132) versus 114 (95% CI 107--120) with *p* = .0142 for STEMI patients treated with pPCI in 2019 versus 2020, respectively.

![Change in absolute number of patients admitted for interventional cardiology procedures in two‐month time periods in 2019 and 2020 in Poland (*p* \< .001) \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](CCD-9999-na-g001){#ccd29134-fig-0001}

Of all patients who underwent invasive diagnostic or treatment during 2‐month period, 362 (2.6%) were COVID‐19 (suspected or confirmed by an approved RT‐PCR test). Baseline characteristic and procedural details and outcomes of COVID‐19 positive/suspected versus non‐COVID‐19 patients are shown in Table [1](#ccd29134-tbl-0001){ref-type="table"} with PS matching adjustment on outcomes in Table [2](#ccd29134-tbl-0002){ref-type="table"}.

###### 

Comparison of COVID‐19 versus non‐COVID‐19 patients who underwent percutaneous coronary diagnostic and treatment in Poland

  Variable                                              Measure/levels     Non‐COVID‐19       COVID‐19                                        *p*
  ----------------------------------------------------- ------------------ ------------------ ----------------------------------------------- -----------------------------------------------
                                                        *n*                13,388             362                                             
  Age, years                                            Mean (±*SD*)       66.93 (±10.88)     64.84 (±12.48)                                  .0003[\*](#ccd29134-note-0001){ref-type="fn"}
  Gender                                                *n*                13,316             358                                             .3807
  Female                                                4,423 (33.22%)     111 (31.01%)                                                       
  Male                                                  8,893 (66.78%)     247 (68.99%)                                                       
  Diabetes mellitus                                     *n*                13,404             362                                             
  1                                                     2,974 (22.19%)     65 (17.96%)        .0623                                           
  Previous stroke                                       *n*                13,404             362                                             
  1                                                     428 (3.19%)        15 (4.14%)         .2903                                           
  Previous MI                                           *n*                13,404             362                                             
  1                                                     3,989 (29.76%)     68 (18.78%)        .0000[\*](#ccd29134-note-0001){ref-type="fn"}   
  Previous PCI                                          *n*                13,404             362                                             
  1                                                     4,707 (35.12%)     69 (19.06%)        .0000[\*](#ccd29134-note-0001){ref-type="fn"}   
  Previous CABG                                         *n*                13,404             362                                             
  1                                                     663 (4.95%)        16 (4.42%)         .8051                                           
  Smoking                                               *n*                13,404             362                                             
  1                                                     2,901 (21.64%)     100 (27.62%)       .0081[\*](#ccd29134-note-0001){ref-type="fn"}   
  Hypertension                                          *n*                13,404             362                                             
  1                                                     9,232 (68.87%)     184 (50.83%)       .0000[\*](#ccd29134-note-0001){ref-type="fn"}   
  Chronic kidney disease                                *n*                13,404             362                                             
  1                                                     873 (6.51%)        23 (6.35%)         1.0000                                          
  COPD                                                  *n*                13,404             362                                             
  1                                                     492 (3.67%)        18 (4.97%)         .2021                                           
  Access site during angiogram                          *n*                11,354             345                                             .0000[\*](#ccd29134-note-0001){ref-type="fn"}
  Femoral                                               1,299 (11.44%)     70 (20.29%)                                                        
  Radial                                                9,933 (87.48%)     269 (77.97%)                                                       
  Other                                                 122 (1.07%)        6 (1.74%)                                                          
  Killip class on admission                             *n*                9,346              290                                             .0000[\*](#ccd29134-note-0001){ref-type="fn"}
  1                                                     8,409 (89.97%)     225 (77.59%)                                                       
  2                                                     582 (6.23%)        32 (11.03%)                                                        
  3                                                     189 (2.02%)        17 (5.86%)                                                         
  4                                                     166 (1.78%)        16 (5.52%)                                                         
  Angiography result                                    *n*                11,354             345                                             .0000[\*](#ccd29134-note-0001){ref-type="fn"}
  No critical lesions                                   2,484 (21.88%)     41 (11.88%)                                                        
  No atherosclerosis                                    903 (7.95%)        19 (5.51%)                                                         
  Single‐vessel disease                                 3,221 (28.37%)     105 (30.43%)                                                       
  Multivessel disease                                   3,809 (33.55%)     143 (41.45%)                                                       
  Multivessel disease with LMCA                         905 (7.97%)        33 (9.57%)                                                         
  LMCA only                                             32 (0.28%)         4 (1.16%)                                                          
  Decision based on angiography                         *n*                4,835              81                                              .0187[\*](#ccd29134-note-0001){ref-type="fn"}
  Further assessment                                    58 (1.20%)         4 (4.94%)                                                          
  CABG                                                  333 (6.89%)        2 (2.47%)                                                          
  PCI ad hoc                                            39 (0.81%)         0 (0.00%)                                                          
  Elective PCI                                          113 (2.34%)        0 (0.00%)                                                          
  Heart team consultation                               539 (11.15%)       8 (9.88%)                                                          
  Conservative treatment                                3,753 (77.62%)     67 (82.72%)                                                        
  FFR during PCI                                        *n*                8,518              279                                             
  1                                                     190 (2.23%)        1 (0.36%)          .0330[\*](#ccd29134-note-0001){ref-type="fn"}   
  IVUS during PCI                                       *n*                8,518              279                                             
  1                                                     264 (3.10%)        0 (0.00%)          .0004[\*](#ccd29134-note-0001){ref-type="fn"}   
  OCT during PCI                                        *n*                8,518              279                                             
  1                                                     9 (0.11%)          1 (0.36%)          .2756                                           
  Total amount of contrast used during procedure, ccm   *n*                12,836             354                                             .0000[\*](#ccd29134-note-0001){ref-type="fn"}
  Mean (±*SD*)                                          126.93 (±76.56)    145.55 (±77.14)                                                    
  Mean 95% CI                                           (125.60; 128.25)   (137.48; 153.61)                                                   
  Total radiation dose during procedure, mGy            *n*                12,835             353                                             .0002[\*](#ccd29134-note-0001){ref-type="fn"}
  Mean (±*SD*)                                          597.21 (±634.18)   670.11 (±588.90)                                                   
  Mean 95% CI                                           (586.24; 608.18)   (608.46; 731.75)                                                   
  Stent type                                            *n*                8,518              279                                             .6094
  BMS                                                   7 (0.08%)          0 (0.00%)                                                          
  BVS                                                   7 (0.08%)          0 (0.00%)                                                          
  DES                                                   7,037 (82.61%)     239 (85.66%)                                                       
  DES, BMS                                              2 (0.02%)          0 (0.00%)                                                          
  No stent used                                         1,465 (17.20%)     40 (14.34%)                                                        
  Death during procedure                                *n*                13,404             362                                             
  1                                                     56 (0.42%)         6 (1.66%)          .0056[\*](#ccd29134-note-0001){ref-type="fn"}   
  MI during PCI                                         *n*                8,518              279                                             
  1                                                     7 (0.08%)          0 (0.00%)          1.0000                                          
  No‐reflow during PCI                                  *n*                8,518              279                                             
  1                                                     69 (0.81%)         2 (0.72%)          1.0000                                          
  Bleeding at the puncture site during PCI              *n*                8,518              279                                             
  1                                                     12 (0.14%)         1 (0.36%)          .3425                                           
  Coronary artery perforation during PCI                *n*                8,518              279                                             
  1                                                     18 (0.21%)         0 (0.00%)          1.0000                                          

*p*\<.05 was considered meaningful.

###### 

Comparison of COVID‐19 versus non‐COVID‐19 patient\'s outcome after propensity score adjustment

  Variable                     Measure/levels     Non‐COVID‐19       COVID‐19   *p*
  ---------------------------- ------------------ ------------------ ---------- -------
  Contrast volume ccm          *n*                3,470              347        .1282
  Mean (±*SD*)                 139.74 (±76.01)    145.69 (±77.65)               
  Mean 95% CI                  (137.21; 142.27)   (137.49; 153.89)              
  Radiation in Gy              *n*                3,470              347        .1321
  Mean (±*SD*)                 650.14 (±656.96)   668.17 (±584.83)              
  Mean 95% CI                  (628.27; 672.00)   (606.42; 729.92)              
  Death during procedure/PCI   *n*                3,470              347        .1862
  Yes                          32 (0.92%)         6 (1.73%)                     

There were 2,421 patients treated with pPCI for STEMI during the 2‐month timeframe, of which 145 (6%) were COVID‐19 (suspected or confirmed by an approved RT‐PCR test). Baseline characteristic and procedural details and outcomes of COVID‐19 positive/suspected versus non‐COVID‐19 patients with PS matching adjustment on outcomes are shown in Tables [3](#ccd29134-tbl-0003){ref-type="table"} and [4](#ccd29134-tbl-0004){ref-type="table"}.

###### 

Comparison of COVID‐19 versus non‐COVID‐19 STEMI patients who underwent percutaneous coronary diagnostic and treatment in Poland

  Variable                                        Measure/levels     Non‐COVID‐19       COVID‐19                                        *p*
  ----------------------------------------------- ------------------ ------------------ ----------------------------------------------- -----------------------------------------------
                                                  *n*                2,276              145                                             
  Age, years                                      Mean (±*SD*)       65.43 (±12.23)     63.19 (±12.55)                                  .0332[\*](#ccd29134-note-0104){ref-type="fn"}
  Gender                                          *n*                2,260              143                                             .3570
  Female                                          731 (32.35%)       41 (28.67%)                                                        
  Male                                            1,529 (67.65%)     102 (71.33%)                                                       
  Diabetes mellitus                               *n*                2,278              145                                             .4496
  1                                               384 (16.86%)       21 (14.48%)                                                        
  Previous stroke                                 *n*                2,278              145                                             .8516
  1                                               69 (3.03%)         4 (2.76%)                                                          
  Previous MI                                     *n*                2,278              145                                             .2449
  1                                               363 (15.94%)       18 (12.41%)                                                        
  Previous PCI                                    *n*                2,278              145                                             .1550
  1                                               400 (17.56%)       19 (13.10%)                                                        
  Previous CABG                                   *n*                2,278              145                                             .0844
  1                                               24 (1.05%)         0 (0.00%)                                                          
  Smoking                                         *n*                2,278              145                                             .1265
  1                                               708 (31.08%)       54 (37.24%)                                                        
  Hypertension                                    *n*                2,278              145                                             .0078
  1                                               1,311 (57.55%)     67 (46.21%)                                                        
  Chronic kidney disease                          *n*                2,278              145                                             .5952
  1                                               75 (3.29%)         6 (4.14%)                                                          
  COPD                                            *n*                2,278              145                                             .2986
  1                                               61 (2.68%)         2 (1.38%)                                                          
  Killip class                                    *n*                1,756              124                                             .2357
  1                                               1,446 (82.35%)     98 (79.03%)                                                        
  2                                               190 (10.82%)       12 (9.68%)                                                         
  3                                               42 (2.39%)         7 (5.65%)                                                          
  4                                               78 (4.44%)         7 (5.65%)                                                          
  Arterial access site                            *N*                2,055              143                                             .0388[\*](#ccd29134-note-0104){ref-type="fn"}
  Other                                           15 (0.73%)         2 (1.40%)                                                          
  Radial left                                     241 (11.73%)       12 (8.39%)                                                         
  Radial right                                    1,501 (73.04%)     96 (67.13%)                                                        
  Femoral                                         298 (14.50%)       33 (23.08%)                                                        
  Angiography finding                             *n*                2,055              143                                             .4308
  No critical lesions                             58 (2.82%)         4 (2.80%)                                                          
  No atherosclerosis                              21 (1.02%)         2 (1.40%)                                                          
  Single vessel disease                           940 (45.74%)       60 (41.96%)                                                        
  Multivessel disease                             914 (44.48%)       63 (44.06%)                                                        
  Multivessel disease with LMCA                   116 (5.64%)        12 (8.39%)                                                         
  LMCA only                                       6 (0.29%)          2 (1.40%)                                                          
  Time from pain to FMC, min                      *n*                1,618              105                                             .8922
  Mean (±*SD*)                                    226.77 (±282.07)   249.13 (±306.70)                                                   
  Mean 95% CI                                     (213.02; 240.53)   (189.78; 308.49)                                                   
  Time from pain to inflation or angiogram, min   *n*                1,560              101                                             .1338
  Mean (±*SD*)                                    309.90 (±279.09)   354.33 (±313.35)                                                   
  Mean 95% CI                                     (296.04; 323.76)   (292.47; 416.19)                                                   
  Time from FMC to inflation or angiogram, min    *n*                1,710              123                                             .0323[\*](#ccd29134-note-0104){ref-type="fn"}
  Mean (±*SD*)                                    111.57 (±133.46)   141.08 (±179.11)                                                   
  Mean 95% CI                                     (105.24; 117.90)   (109.11; 173.05)                                                   
  Death during procedure                          *n*                2,278              145                                             .0441[\*](#ccd29134-note-0104){ref-type="fn"}
  1                                               26 (1.14%)         5 (3.45%)          .0345[\*](#ccd29134-note-0104){ref-type="fn"}   
  No‐reflow during PCI                            *n*                2,160              136                                             .3522
  1                                               36 (1.67%)         1 (0.74%)          .7223                                           
  Bleeding at the puncture site during PCI        *n*                2,160              136                                             .6211
  1                                               2 (0.09%)          0 (0.00%)          1.0000                                          

*p*\<.05 was considered meaningful.

###### 

Comparison of COVID‐19 versus non‐COVID‐19 STEMI patient\'s outcome after propensity score adjustment

  Variable                                                 Measure/levels     Non‐COVID‐19       COVID‐19   *p*
  -------------------------------------------------------- ------------------ ------------------ ---------- -------
  Time from pain to FMC, min                               *n*                970                97         .9723
  Mean (±*SD*)                                             201.69 (±237.99)   224.38 (±283.09)              
  Mean 95% CI                                              (186.70; 216.69)   (167.33; 281.44)              
  Time from pain to inflation or angiogram, min            *n*                970                97         .1018
  Mean (±*SD*)                                             301.27 (±268.40)   346.98 (±305.24)              
  Mean 95% CI                                              (284.36; 318.18)   (285.46; 408.50)              
  Time from first contact to inflation or angiogram, min   *n*                970                97         .0282
  Mean (±*SD*)                                             99.57 (±105.40)    122.60 (±120.90)              
  Mean 95% CI                                              (92.93; 106.22)    (98.23; 146.96)               
  Death during procedure                                   *n*                970                97         .9259
  Yes                                                      11 (1.13%)         1 (1.03%)                     

5. DISCUSSION {#ccd29134-sec-0009}
=============

Best to our knowledge, this is one of the first detailed national analysis on the impact of SARS‐CoV‐2 pandemic on interventional cardiology procedures as well as the first presentation of baseline characteristics and immediate outcome of over 300 COVID‐19 confirmed/suspected patients. Some studies and preliminary reports have suggested that a substantial decrease in interventional cardiology procedures has been observed with longer time delays to intervention, especially among STEMI COVID‐19 patients[^9^](#ccd29134-bib-0009){ref-type="ref"}, [^10^](#ccd29134-bib-0010){ref-type="ref"} and a shift toward acute cases.[^11^](#ccd29134-bib-0011){ref-type="ref"}, [^12^](#ccd29134-bib-0012){ref-type="ref"}

Poland represents a high volume country for interventional cardiology procedures with a well‐established hospital referral network program for ACS. The magnitude of SARS‐CoV‐2 pandemic places Poland among moderately affected countries with over 21,000 confirmed cases so far and over 1,000 deaths with governmental lockdown measures being implemented early on.[^13^](#ccd29134-bib-0013){ref-type="ref"} Yet, the negative impact on the healthcare system seems substantial. The shift toward acute cases (ACS) is evident, but what raises even more concern is an almost 40% decrease in the absolute number of interventional procedures in acute setting (STEMI, NSTEMI) when compared with the analogous time frame in 2019 and over 70% decrease instable angina procedures. The well‐functioning network of catheterization labs has been shattered by closures and temporary suspensions (almost 10% of all labs) and transformation into COVID‐19 hospitals/departments in order to accommodate the infectious patients. Resources are now predominantly redirected into the treatment of COVID‐19 patients.

On the other hand, no significant delays have been observed in a STEMI cohort in 2020 when comparing with 2019. Moreover, a significantly shorter time of a mean 13 min from FMC to angiography was observed in 2020. Maybe this is associated with an overall fewer cases and EMS and cath labs running on half empty which facilitates patient transfer and management.

Although COVID‐19 patients in 2020 were more often those with critical lesions in baseline angiography (17 vs 29%) versus those non‐COVID‐19, they were less frequently referred for invasive treatment (78 vs 83%). Modern imaging techniques, which prolong PCI procedure like intravascular ultrasound and fractional flow reserve, were also less frequently used in COVID‐19 patients. Total amount of contrast and radiation used during interventional procedures were similar in COVID‐19 and non‐COVID‐19 patients after PS adjustment.

While we have observed a low rate of periprocedural complications and similar periprocedural outcome in COVID‐19 versus non‐COVID‐19 patients with STEMI after PS adjustment, there was a significantly longer delay in COVID‐19 patients from FMC until intervention (\~ mean of 30 and 23 min after PS adjustment). The proper preparation of the cathlab staff and dealing with potentially infected patient certainly generates additional delays, which cannot be overcome at least at the initial phase of the pandemic when we all learn how to cope with new issues. The long‐term impact of this finding on survival; however, remains unknown. The main issue is if all who have indications make it to the cathlab. Moreover, we may see consequences of these events in the near future mainly as an increase of heart failure incidence and hospitalizations.

The chance to perform interventional procedure in a COVID‐19 confirmed/suspected case is 1 in 39 in general or 1 in 17 when dealing with STEMI patients in Poland and the risk of becoming infected as a PCI operator is currently 1.7% per 2 months and seems low but that numbers will certainly vary in the end.

It is vital to provide recommendations on a national/international level for the management of COVID‐19 and non‐COVID‐19 patients; however, these days, this might not be the case anymore since anyone may be infected. Therefore, cathlab staff needs to adhere to the new reality that will probably stay with us for months if not years and considering every patient as a potential COVID‐19 infection. Constant monitoring of the number of procedures and outcomes of all patients should be undertaken. Elective patients should be carefully screened and monitored, preferably using telemedicine for the indications for urgent or accelerated coronary diagnostic and treatment. Patients with ongoing rest chest pain should be educated not to delay emergency calls.

The study has limitations which include the lack of further follow‐up of patients beyond catheterization room and the analysis represents only situation in one country (Poland) which may not be universal due to various presentation of SARS‐CoV‐2 pandemic worldwide.

6. CONCLUSIONS {#ccd29134-sec-0010}
==============

The SARS‐CoV‐2 pandemic has had a tremendous effect on interventional cardiology procedures in Poland so far. There is an absolute reduction in the number of interventional procedures both in acute and elective settings in comparison to 2019 and in a significant shift into acute procedures in terms of fraction of all procedures. COVID‐19 confirmed/suspected patients do not differ in terms of procedural and baseline characteristics and reveal similar outcomes when treated with percutaneous coronary interventions. Longer time delays from FMC until intervention have been observed in a STEMI cohort of COVID‐19 patients.
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